ClinicalTrials.gg
RecruitingNCT05988736Updated Aug 14, 2023

Comparison Between McGrath and Macintosh Laryngoscopes for DLT Intubation in Thoracic Surgery Patients.

An interventional study of MaCintosh Laryngoscope (DL) and McGrath Laryngoscope (VL) in Thoracic Diseases, Thoracic Neoplasms and Thoracic Empyema, sponsored by Aga Khan University. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Aga Khan University · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2022, registered Jul 2023).
  • Started Jun 2022; still recruiting 4 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this RCT is to compare outcome with McGrath vs Macintosh laryngoscopes among patients undergoing thoracic surgery. The main questions it aims to answer are,

  1. Rate of successful intubation at first attempt and
  2. Time for intubation required with each device. Participants are required to sign the informed consent for, they will be placed in two groups, Group A: Macintosh (DL) Group B: McGrath (VL) Researchers will compare in Group A: Macintosh (DL) and Group B: McGrath (VL) the differences in rate of successful intubation at first attempt and time for intubation required with each device.
02

Conditions studied

  • Thoracic Diseases
  • Thoracic Neoplasms
  • Thoracic Empyema
03

In context

Thoracic Diseases

72 studies on the registry are indexed under Thoracic Diseases; 13 are open to participants now.

This study's planned enrollment of 84 is above the median of 65 across 52 interventional studies indexed under Thoracic Diseases.

Browse Thoracic Diseases studies →

Lead sponsor

Aga Khan University is the lead sponsor of 294 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years
  • American Society of Anaesthesiologists physical status (ASA) I, II, III
  • Elective thoracic surgery patients, requiring one lung ventilation.

Exclusion criteria

Exclusion Criteria:

  • Patients requiring rapid sequence induction
  • Patients with a structural problem in the airway on chest radiography
  • History of difficult intubation
  • Planned tracheostomy \ the presence of a tracheostomy

    • Patients with a >35 kg\m2. Who at risk of regurgitation\ Aspiration
    • Anticipated Difficult Airway (Mallampati IV)
    • Pre-existing sore throat or hoarseness, or recent respiratory infection (\<15 days)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Group A

    Device: MaCintosh Laryngoscope (DL)

  • Active comparator
    Group B

    Device: McGrath Laryngoscope (VL)

Interventions

  • DeviceMaCintosh Laryngoscope (DL)

    A conventional Laryngoscope. It is battery powered, with a detachable MaCintosh blade that contains a light source.

  • DeviceMcGrath Laryngoscope (VL)

    A video Laryngoscope that has a high-resolution video camera, and a light source at the cone end of the blade allowing for direct and indirect viewing of the glottis

06

What researchers measure

Primary outcomes

  1. Time required for correct placement of the Double Lumen Tube (DLT).

    Time will be measured in seconds during laryngoscopy while placement of Double Lumen Tube (DLT) until appearance of end tidal carbon dioxide on capnograph.

    Time frame: During intervention time period

  2. Successful Intubation at first attempt.

    The number of times the laryngoscope will be inserted.

    Time frame: immediately after Intervention.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2023, 17 months after the start.

Of 27 interventional studies with no phase under Thoracic Diseases, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 42. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2023
First posted
Aug 14, 2023
StartActual
Jun 15, 2022
Primary completionEst.
Dec 1, 2023
CompletionEst.
Dec 31, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05988736
Responsible party
Sadique Ali (Principal Investigator, Aga Khan University) — Principal investigator
First posted
Aug 14, 2023
Start date
Jun 15, 2022
Primary completion
Dec 1, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Aug 14, 2023

Study contacts

sadique Wadho, MBBS
Contact
sadique.ali@aku.edu
+923322792932
Khalid Samad, MBBS, FCPS
Contact
khalid.samad@aku.edu
+923343311603

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion